PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

PARP inhibitors are synthetically lethal with BRCA1/2 mutations, and in this setting, accumulation of DNA damage leads to cell death. Because increased DNA damage and subsequent immune activation can prime an anti-tumor immune response, we studied the impact of olaparib ± immune checkpoint blockade...

Descripción completa

Detalles Bibliográficos
Autores principales: Staniszewska, Anna D., Armenia, Joshua, King, Matthew, Michaloglou, Chrysiis, Reddy, Avinash, Singh, Maneesh, San Martin, Maryann, Prickett, Laura, Wilson, Zena, Proia, Theresa, Russell, Deanna, Thomas, Morgan, Delpuech, Oona, O’Connor, Mark J., Leo, Elisabetta, Angell, Helen, Valge-Archer, Viia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225208/
https://www.ncbi.nlm.nih.gov/pubmed/35756843
http://dx.doi.org/10.1080/2162402X.2022.2083755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225208/
https://www.ncbi.nlm.nih.gov/pubmed/35756843
http://dx.doi.org/10.1080/2162402X.2022.2083755

Ejemplares similares